Pathstone Family Office’s Evogene EVGN Stock Holding History

Pathstone Family Office’s Portfolio EVGN Stock Details EVGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-491	Closed	-$23K	–	880
2020 Q4	$23K	Buy	+491	New	+$17.3K	﹤0.01%	659

Other funds holding EVGN

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Pathstone Family Office's EVGN Position: Q1 2021 in Review

Pathstone Family Office sold out of Evogene (EVGN) in Q1 2021, closing a stake of 491 shares — an estimated $23K sold.

Pathstone Family Office first reported a position in EVGN in Q4 2020 and held it in 1 quarter. The position peaked at $23K in Q4 2020. 45 funds tracked by Wall St. Rank hold EVGN as of Q1 2021.

Pathstone Family Office reported no remaining Evogene position as of Q1 2021 after selling out during the quarter.
Pathstone Family Office sold 491 Evogene shares in Q1 2021, an estimated $23K.
Pathstone Family Office first reported a position in Evogene in Q4 2020 and held it in 1 quarter.
Pathstone Family Office's Evogene position peaked at $23K in Q4 2020.
45 funds tracked by Wall St. Rank held Evogene as of Q1 2021.

Based on Pathstone Family Office's 13F filing for Q1 2021, filed 14 May 2021.